ASX 200 stock Cochlear plunges on lack lustre results
Cochlear shares plummeted on Friday after the HY26 results but what exactly triggered such a sharp reaction from investors and could a stronger second half pave the way for a recovery ahead?
Cochlear Limited (ASX: COH)
has declined over 17% by afternoon trade on Friday after it reported a softer HY26 result due to delays in the rollout of the Cochlear Nucleus Nexa system.
Management stated that product registration and contract renewals took longer than expected, especially in cases where price increases were proposed.
Although approvals across Europe, Asia Pacific and the US were secured around mid-year, product availability expanded gradually across the half rather than at once.
By December 2025, about 80% of units sold were the new Nexa system and management pointed to market share gains later in the half as adoption improved.
The Nucleus Nexa system was introduced as the world’s first upgradeable smart cochlear implant after 20 years of research and development.
Despite stronger uptake in recent months, HY26 revenue increased only 1% to $1,176 million and declined 2% in constant currency terms.
Underlying net profit decreased 9% to $195 million, EBIT margin fell to 22% from 25% last year and statutory net profit declined 21% to $161.5 million.
Cochlear implants generated $724 million which accounted for 62% of group revenue while Services contributed $312 million and Acoustics delivered $140 million for the half.
The board declared an interim dividend of $2.15 per share which was unchanged from last year and represents a payout ratio of 72% while current annual yield is around 2.11%.
The company has a market capitalisation of $13.31 billion and maintains a strong balance sheet with net cash of $173 million although working capital rose due to higher inventory related to the new product launch.
Management now expects FY26 underlying net profit to be at the lower end of the $435 to $460 million range while the current P/E ratio is around 34 and return on equity is impressive as it remains above 20%.
The company expects a stronger second half supported by wider Nexa availability, better Services performance and improved momentum in Acoustics.
There is also currency risk as guidance assumes AUD/USD of 66 cents and AUD/EUR of 56 cents and if the Australian dollar stays at current levels, underlying net profit could decline by about $30 million which means investors should be cautious and closely monitor execution in the second half to see whether Cochlear can restore growth and justify its premium position in the global hearing implant market.
(Source: Company Announcements)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
